Abstract: Objective To explore the clinical value of dynamic monitoring of serum markers after 131I radiotherapy in patients of Graves disease. Methods The serum levels of TRAb, FT3, FT4, TSH, TGAb and TMAb in 350 patients with Graves disease and 135 normal controls were measured before and at 3, 6, 9 and 12 months after 131I radiotherapy. Results The serum levels of TRAb, FT3, FT4, TGAb and TMAb in Graves disease group before treatment was obviously higher than that of control group (35.80±1.02 vs 6.81±2.10, 18.86±3.40 vs 10.10±2.13, 41.64±7.82 vs 18.10±5.88, 31.24±4.12 vs 1.98±2.10 and 32.10±5.02 vs 2.98±1.18). The serum levels of above markers at 3 months after treatment were obviously lower than that of before treatment P＜0.01）, and these markers were gradual declined from 6 months to 12 months. The TSH levels before treatment in Graves disease group were obviously lower than that of control group (1.85±1.12 vs 7.54±3.02, P＜0.01 ), and it gradual rose from 6 months to 12 months. In comparison of serum markers between different time points after treatment and control group, time to achieve normality of TRAb, FT3 and FT4 were 12 months, 6 months and 9 months respectively. Conclusion Dynamic monitoring of serum markers might have clinical significance in the diagnosis of Graves disease and in the monitoring and efficacy evaluation of 131I radiotherapy.
李三喜，陈森良
. Dynamic Monitoring of Serum Markers After 131I Radiotherapy in Patients of Graves Disease[J]. Labeled Immunoassays and Clinical Medicine, 2013
, 20(6)
: 384
-386
.
DOI: 10.11748/bjmy.issn.1006-1703.2013.06.005
